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Abstract
Introduction: Identifying and managing patients with prediabetes is important. The
study aims to investigate the association of body mass index (BMI) with  impaired
fasting  glucose  (IFG),  β-cell  dysfunction,  and  insulin  resistance  in  nondiabetic
Chinese individuals. 
Material and methods: This was a cross-sectional study of consecutive nondiabetic
individuals  enrolled  between  January  2014  and  January  2015,  divided  into  NFG
[normal fasting glucose, fasting blood glucose (FBG) < 5.6 mmol/L) and IFG (n =
450; FBG ≥ 5.6 mmol/L) groups. Restricted cubic splines and piecewise-regression
were  used  to  model  the  association  of  IFG,  impaired  β-cell  function,  and  insulin
resistance with BMI. Stratified analyses were performed across sex and age.
Results: A total of 900 NFG and 450 IFG individuals were enrolled, with a median
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age of 41 (30–49) years and 1076 males (79.7%). After adjusting for age and sex, the
restricted  cubic  splines  showed  that  the  risk  of  IFG  was  increasing  rapidly  until
around 27.96 kg/m2 of BMI and then started to plateau afterward (P for non-linearity
=  0.010),  which  was  similar  in  males  and  individuals  ≤45 years  old  (P for  non-
linearity < 0.001 and = 0.007, respectively). The risk of  insulin resistance increased
and β-cell dysfunction decreased as the BMI increased in all participants (both P for
non-linearity > 0.05), consistent with the results in males, females, and ≤ 45 and > 45
year olds. 
Conclusions: The risk of IFG does not rise linearly as the BMI increases, and higher
BMI seems to decelerate the rise of the risk. 
Key  words:  insulin-secreting  cells;  insulin  resistance;  blood  glucose;  body  mass
index
Introduction
The prevalence of diabetes in Chinese adults has been increasing rapidly since
2000, with an annual growth rate of 0.72% (95% CI: 0.34–1.10%) [1]. In a nationally
representative  cross-sectional  survey  carried  out  in  2013,  the  estimated  overall
prevalence of diabetes among adults in China was 10.9%, and that for prediabetes was
35.7% [2]. Once developed, type 2 diabetes (T2DM) is an irreversible condition [3].
Individuals with prediabetes will eventually progress to overt diabetes, but it can be
delayed  with  the  appropriate  changes  in  lifestyle  habits  and  with  drugs  when
necessary. Individuals with prediabetes will have no signs or symptoms but will show
impaired fasting glucose (IFG). Identifying and managing patients with prediabetes is
important because chronic hyperglycaemia of diabetes can lead to multiorgan damage
resulting in renal, neurological, cardiovascular, and other serious complications  [3]
and is associated with significant morbidity and mortality [4]. 
The major underlying pathophysiology of T2DM in the Chinese population is the
same as in other populations, i.e. β-cell dysfunction and insulin resistance [5]. Insulin
resistance is defined as an impaired peripheral sensitivity to normal or elevated insulin
levels. Compensatory hyperinsulinaemia occurs when insulin secretion increases to
maintain blood glucose levels at normal levels. Hence, high fasting insulin (FINS)
levels may indicate insulin resistance [6]. The abnormal function of pancreatic islet β-
cells is characterized by impairments ranging from impaired insulin pulse secretion to
the  lack of  insulin  secretion in  the first  phase and increased compensation in  the
second phase [7]. In the decompensated stage, both the 1- and 2-phase secretions are
decreased. In the United Kingdom Prospective Diabetes Study (UKPDS), the  β-cell
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function was lower by about 50% when fasting hyperglycaemia was diagnosed [8].
High  adiposity,  as  reflected  by  a  high  body mass  index  (BMI),  is  the  most
important  independent  risk  factor  for  T2DM  [9].  Homeostasis  model  assessment
(HOMA) equations are tools used to estimate insulin resistance. HOMA-IR is used to
assess insulin resistance, while HOMA-β is used to assess pancreatic β-cell function
[10]. A study in Caucasians showed that the HOMA-IR is dependent upon sex, age,
and  BMI  categories,  with  obese  people  having  high  HOMA-IR  [11].  Both  β-cell
dysfunction and insulin resistance contribute to high levels of fasting blood glucose
(FBG) and the progressive deterioration from impaired glucose regulation (IGR) to
T2DM; when IGR signs start to manifest, FBG may still be in the normal range [12].
The degree of β-cell dysfunction is a determinant for the FBG levels, with decreased
insulin secretion by β-cells and peripheral insulin resistance contributing to increased
FBG levels  [13].  In  subjects  with  T2DM,  β-cell  secretory capacity  is  reduced by
approximately  75%  when  the  FBG  levels  increase  [14].  Previous  studies  have
suggested that  deterioration of basal  and early-phase insulin  secretion,  rather  than
insulin sensitivity, is crucial to the progression from normal glucose tolerance (NGT)
to T2DM [15].
Nevertheless, there is a lack of data about the relationship between FBG and β-
cell function during the progression from NFG to IFG according to the different BMI
levels. Therefore, this study aimed to investigate the association of BMI with IFG, β-
cell dysfunction, and insulin resistance in nondiabetic Chinese individuals. The results
could help identify the individuals at higher risk of progression to T2DM in whom
early lifestyle changes should be undertaken.
Material and methods
Study design and participants
This cross-sectional study enrolled consecutive nondiabetic individuals from the
Physical Examination Centre of our Hospital  from January 2014 to January 2015.
This study was approved by the Ethics Committee of our Hospital. All participants
provided written informed consent.
The inclusion criteria were as follows: 1) 18–80 years of age; 2) no medical
history of  heart  disease,  brain disease,  lung disease,  high blood pressure (systolic
blood  pressure  [SBP]  ≥  140  mmHg and/or  diastolic  blood  pressure  [DBP]  ≥  90
mmHg measured 3 times on different days, without medication), blood lipid disorders
(total cholesterol [TC] ≥ 5.2 mmol/L, low-density lipoprotein cholesterol [LDL-C] ≥
3.4 mmol/L, triglyceride [TG] ≥ 1.7 mmol/L, or high-density lipoprotein cholesterol
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[HDL-C]  <  1.0  mmol/L,  without  medication),  chronic  hepatitis  (viral  hepatitis,
autoimmune liver disease, drug-induced liver disease, liver cancer and cirrhosis, and
no history of medication), and chronic kidney disease (chronic glomerulopathy, renal
tubular  disease,  interstitial  nephritis,  and  renal  vascular  disease,  and  the  serum
creatinine is normal), and 3) markers of liver and kidney functions were all within the
normal  range.  The  exclusion  criteria  were  1)  FBG  ≥  7.0  mmol/L  or  glycated
hemoglobin  (HbA1c)  ≥  6.5%,  2)  use  of  anti-hypertension  drugs,  anti-dyslipidemia
drugs, or any medications known to affect insulin sensitivity within the past 6 months,
including  weight-loss  drugs,  Chinese  herbal  medicines,  anti-diabetic  drugs,  and
insulin;  3)  severe  organ  dysfunction  or  mental  illness;  or  4)  history  of  diabetes
mellitus, severe anaemia, pancreatitis, acute myocardial infarction, or stroke.
Grouping
According  to  the  diagnostic  criteria  for  IFG  by  the  American  Diabetes
Association (ADA) in the United States  [16],  the individuals  were divided into 2
groups based on FBG: IFG (FBG ≥ 5.6 mmol/L) and NFG (FBG < 5.6 mmol/L). 
Data collection and definitions
Basic demographic data (i.e. age, sex, body height, and weight) were collected.
Height and weight were measured to the nearest 0.1 cm and 0.1 kg by the same well-
trained examiner. Body mass index (BMI) was calculated as follows:
 body weight (kg)/[height (m)]2. 
Fasting (overnight) serum samples were collected from a peripheral vein. Serum
samples were stored at –80°C. TC, HDL-C, LDL-C, and TG levels were measured by
colorimetric  enzymatic  assays  using  a  7170 autoanalyzer  (Hitachi,  Tokyo,  Japan).
Reference intervals for TC, HDL-C, LDL-C, and TG were 3.62–5.70 mmol/L, 1.03–
1.55 mmol/L, 1.81–3.36 mmol/L, and 0.56–1.70 mmol/L, respectively  [17]. HbA1c
was measured using a Variant II HbA1c analyser (Bio-Rad Laboratories, Hercules,
CA, USA). Alanine aminotransferase (ALT), aspartate aminotransferase (AST), FBG,
HbA1c,  and  FINS  levels  were  measured  routinely  at  the  central  biochemistry
laboratory of our hospital. 
The HOMA-IR and HOMA-β were determined. HOMA-IR was calculated according
to the following formula:
HOMA-IR = [FBG (mmol/L) × FINS (μIU/mL)]/22.5, 
And HOMA-β was calculated as follows:
HOMA-β = [20× FINS (μIU/mL)]/[FBG (mmol/L)–3.5]. 
Insulin  resistance  was  defined as  higher  than  the  75th percentile  of  HOMA-IR in
participants with a normal BMI and normal fasting glucose [18], which was 2.726 in
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this study. Impaired β-cell function was defined as lower than the 25th percentile of the
HOMA-β in participants with a normal BMI and normal fasting glucose  [12,  18],
which was 73.988 in this study.
Statistical analysis
Continuous data were presented as mean ± standard deviation or median (upper
and lower quartiles)  and analysed  using Student’s  t-test.  Categorical  variables  are
presented as frequencies and were analysed using the chi-square test. The significance
of  the  mean  differences  for  the  indexes  of  insulin  resistance  and  β-cell  function
(HOMA-IR,  HOMA-β,  and  FINS)  was  tested  using  general  linear  models  after
adjustment for age, sex, and BMI. The associations between insulin resistance, β-cell
dysfunction, and IFG with BMI were evaluated by restricted cubic spline regression,
adjusting for age and sex. The number of dots was chosen to 4 knots at the 5  th  , 35  th  ,
65  th  , and 95  th   centiles. Piecewise-regression models were then performed to quantify
associations: where there was evidence of non-linearity, a piecewise-regression model
with a single change point was estimated by trying all possible values for the change
point and choosing the value with the highest likelihood. Moreover, stratified analyses
were performed to explore whether the association varied across sex and age. Data
analysis was performed using SPSS 22.0 (IBM, Armonk, NY, USA) and R 4.0.2 (The
R  Project  for  Statistical  Computing,  www.r-project.org).  GraphPad  Prism  8
(GraphPad Software Inc., San Diego, CA, USA) was used to draw the figures. All
tests were two-tailed, and p values < 0.05 were considered statistically significant.  
Results
Characteristics of the participants
A total of 1350 participants, including 900 individuals in the NFG group and 450
in the IFG group, were enrolled from the Physical Examination Centre of our Hospital
between January 2014 and January 2015 and analysed. The mean age was 41 (30–49)
years  and  most  participants  were  male  (79.6%) (Tab.  1).  There  were  significant
differences in age, BMI, and blood pressure between the two groups (all p < 0.05).
In addition, higher levels of TC, TG, and LDL-C and lower levels of HDL-C
were observed in the IFG group (all p < 0.05). Compared with the NFG group, FINS
and HOMA-IR were significantly higher in the IFG group (FINS: 12.75 ± 0.24 vs.
15.35 ± 0.34; HOMA-IR: 2.97 ± 0.06 vs. 4.09 ± 0.09), while HOMA-β was lower
(150.1 ± 2.4 vs. 125.6±3.5) (all p < 0.05). 
Association of IFG, impaired β-cell function, and insulin resistance with BMI
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After adjusting for age and sex, restricted cubic spline regression showed that the
risk of insulin resistance increased rapidly as the BMI increased, and the non-linearity
was not significant (p = 0.725, Fig. 1A), indicating that the risk of insulin resistance
increased as BMI increased, or, in some way, high BMI was a risk factor of insulin
resistance. In contrast, the risk of β-cell dysfunction decreased in an approximately
linear fashion (p for non-linearity = 0.851, Fig. 1B), meaning that the risk of β-cell
dysfunction decreased as BMI increased, or, in some way, high BMI was a protective
factor of β-cell function. Notably, the risk of IFG increased rapidly until around 27.96
kg/m2 of BMI and then started to plateau afterward (p for non-linearity = 0.010, Fig.
1C), indicating that the risk of IFG increased as the BMI increased, but higher BMI
seemed to decelerate the increase of the risk.
Association of IFG, impaired β-cell function, and insulin resistance with BMI by
age 
After stratifying all participants into the 18–45- and > 45-year-old subgroups,
younger individuals showed a lower prevalence of IFG and β-cell dysfunction (both p
< 0.001,  Fig.  2A).  Meanwhile,  no  significant  difference  was  found regarding the
prevalence of insulin resistance. Restricted cubic spline regression showed that the
risk  of  insulin  resistance  increased  and  β-cell  dysfunction  decreased  as  BMI
increased,  and  the  non-linearity  was  not  significant  whether  in  younger  or  older
individuals (all p for non-linearity > 0.05, Fig. 3A, B, D, and E). Consistent with asll
of the individuals, the risk of IFG increased rapidly until around 27.51 kg/m2 of BMI
and then started to plateau afterward in 18–45-year-old individuals (p for non-linearity
= 0.007, Fig. 3C). On the other hand, the non-linearity seemed to disappear in older
individuals (p for non-linearity = 0.212, Fig. 3E). The results suggest that in younger
individuals, the risk of IFG increased as the BMI increased, but higher BMI seemed to
decelerate the increase of the risk, while still being linked to increased risk in older
individuals.
Association of IFG, impaired β-cell function, and insulin resistance with BMI by
sex
Stratified analysis showed that male individuals had a higher prevalence of IFG
and insulin resistance (both p < 0.001, Fig. 2B). Meanwhile, no significant difference
was found regarding the  prevalence  of  β-cell  dysfunction.  Restricted  cubic  spline
regression showed that the risk of insulin resistance increased and impaired β-cell
function  decreased  as  BMI  increased,  and  the  non-linearity  was  not  significant
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whether in male or female individuals (all p for non-linearity > 0.05, Fig. 4A, B, D,
and E). As with all  the individuals,  the risk of IFG increased rapidly until  around
24.26 kg/m2 of BMI and then started to plateau afterward in male individuals (P for
non-linearity < 0.001, Fig. 4C). However, the non-linearity seemed to disappear in
female individuals (p for non-linearity = 0.349, Fig. 4E). Hence, in males, the risk of
IFG  increased  as  the  BMI  increased,  but  higher  BMI  seemed  to  decelerate  the
increase of the risk, while high BMI still increased the risk in females.
Discussion
This  study  aimed  to investigate  the  association  of  BMI  with  IFG,  β-cell
dysfunction,  and insulin resistance  in  nondiabetic  Chinese individuals.  The results
show that the risk of IFG is not rising linearly as the BMI increases, and higher BMI
seems to decelerate the rise of the risk. The findings suggest that the compensated
secretion of β cells might play a valuable role against insulin resistance in high-BMI
individuals.
Overweight  or  obesity  is  a  major  risk  factor  for  prediabetes  and  T2DM.  In
Northeast China, the prevalence of overweight is 42%, the prevalence of obesity is
20.1%, and the prevalence of central obesity is 58.9% in adults with prediabetes [19].
Abdominal obesity accounts for 28.1% of incident cases of diabetes among men and
41.2% among women [20]. FINS and HOMA-IR were higher in the IFG group than
in the NFG group, while HOMA-β was lower in the IFG group. It is consistent with
the  concept  of  progressive  insulin  resistance  and β-cell  dysfunction  from NFG to
T2DM  [14]. High  FBG  is  one  of  the  main  characteristics  of  T2DM.  In  the
postprandial state, T2DM defined by HbA1c levels was associated with both α- and β-
cell  dysfunction  and  impaired  insulin  response  combined  with  non-suppressed
glucagon  [21]. In the fasting state, the liver maintains blood glucose levels for the
brain’s need for glucose. Thus, insulin resistance of the liver plays a key role in high
FBG levels. IFG is an intermediate status between NFG and T2DM, and the present
study showed that HOMA-IR increased from NFG to IFG, which is supported by the
literature [11, 22]. 
In addition to insulin resistance, β-cell dysfunction is well recognized as central
to  the  pathophysiology  of  prediabetes  and  diabetes.  The  earliest  detectable
abnormality in individuals at risk of T2DM is insulin hypersecretion, which aims to
compensate for insulin resistance in peripheral tissues. Nevertheless, T2DM does not
occur  until  the  β-cells  become  unable  to  secrete  enough  insulin  to  overcome
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peripheral insulin resistance. In some Chinese analyses evaluating the role of β-cell
function  in  increasing  FBG,  the  disposition  index,  a  value  representing  β-cell
function, was decreased by 38% in IFG [12], and HOMA-β progressively declined by
33% in IFG and reached a substantial decrease of 41% in the diabetic range of FBG
[23]. Previous studies suggested that the deterioration of basal and early-phase insulin
secretion, rather than insulin sensitivity, is crucial to the progression from NGT to
T2DM [15]. Sun et al. [24] found that in overweight Chinese adolescents with normal
glucose tolerance, insulin resistance progressively increased with increasing BMI, but
the compensatory increase in early insulin  secretion was limited.  Roth et  al.  [25].
found that the OGTT 30-min/120-min insulin ratio was significantly lower in obese
children,  which  indicated  that  these  children  already  had  inadequate  β-cell
compensation for the degree of insulin resistance [25]. In the present study, the cubic
spline  analyses  showed  that  the  risk  of  insulin  resistance  increased  as  the  BMI
increased, meaning that high BMI was a risk factor of insulin resistance. In addition,
the risk of impaired β-cell function decreased as the BMI increased, suggesting that
high  BMI  was  a  protective  factor  of  impaired  β-cell  function.  The  compensated
secretion of β cells might contribute to the phenomenon.
Interestingly, different relationships were observed between younger and older
individuals  and  between  males  and  females.  The  differences  of  IFG  and  β-cell
function in younger and older individuals revealed that the main cause of the higher
prevalence  of  IFG  in  older  individuals  might  be  worse  β-cell  function.  The
disappearance of non-linearity in older individuals might be due to a worse β-cell
function and worse compensated secretion function of β-cells. It is consistent with the
literature showing that β-cell function decreases with age [26, 27]. The differences of
IFG and insulin  resistance in  male  and female individuals  revealed  that  the main
cause of the higher prevalence of IFG in male individuals might be insulin resistance.
In addition, the change point of BMI was lower in males than in whole individuals.
Because of the high prevalence of insulin resistance in men, compensatory insulin
secretion  might  be  more  common  in  men  [28].  Sex  hormones  play  a  role  in
developing insulin resistance and T2DM [28, 29].
It is now recognized that β-cell failure occurs much earlier and is more severe
than previously thought [30]. Individuals with FBG in the upper range have decreased
β-cell  function  and decreased  insulin  sensitivity  before  the  onset  of  diabetes,  and
Asians  are  more  likely  to  have  lower  β-cell  mass  and  insulin  secretory  capacity
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compared with Caucasians  [31],  suggesting that a  small  decline in β-cell  function
could be enough to precipitate progression to overt T2DM in Asians. A study of 1835
Japanese  patients  demonstrated  that  insulin  secretory defect  and decreased  insulin
sensitivity were found in patients with IFG in the range 5.6–6.1  [32]. The present
study showed that insulin resistance and β-cell dysfunction were deteriorated when
FBG was ≥ 5.6 mmol/L. It may suggest that the optimal time to intervene is before the
FBG is ≥ 5.6 mmol/L in the Chinese population, to prevent the progression of T2DM
and its complications. It is supported by a previous study that showed distinct lipid
patterns across FBG levels in different ethnicities [33].
The present study has some limitations. Firstly, we used the HOMA-β to evaluate
pancreatic  β-cell  function.  HOMA-β  is  not  a  precise  index  compared  to  the
hyperglycaemic  clamp,  but  the  clamp is  expensive  and time-consuming,  and it  is
difficult to carry out in the setting of a large-scale epidemiological study. Secondly,
we did not take into account the level of physical activity of the participants, which
might significantly affect FBG, insulin concentration, and insulin resistance. Finally,
males outnumbered females in this study because the population were enrolled at the
hospital’s  medical  examination  centre.  Most  participants  were  men  with  good
economic  conditions,  which  resulted  in  a  limited  analysis  of  female  individuals.
Further studies are necessary to address this issue.
Conclusion
The risk of IFG does not rise linearly as the BMI increases, and higher BMI seems to
decelerate the rise of the risk. The association of BMI with the risk of IFG decelerates
at high BMI values in younger individuals and males. The findings suggest that the
compensated secretion of β cells might play a valuable role against insulin resistance
in high-BMI individuals. These results could help identify individuals at higher risk of
progression to T2DM in whom early lifestyle changes should be undertaken, and it
could contribute personalized management.
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2.76 (2.32, 3.33) 2.94 (2.55, 3.39) < 0.001

































150.1 ± 2.4 125.6 ± 3.5 < 0.001
Normally  distributed  variables  are  expressed  as  mean  ±  standard  deviation  (SD),  while
variables with skewed distribution (age, ALT, AST, TG, FINS, HOMA-IR, and HOMA-β are
expressed  as  medians  [upper  and  lower  quartiles]).  BMI:  — body mass  index;  SBP:  —
systolic blood pressure; DBP: — diastolic blood pressure; ALT: — alanine aminotransferase;
AST: — aspartate aminotransferase; TC: — total cholesterol; TG: — triglyceride; HDL-C: —
high-density lipoprotein cholesterol; LDL-C: — low-density lipoprotein cholesterol; FBG: —
fasting  blood  glucose;  FINS:  —  fasting  insulin;  HOMA-IR:  —  homeostasis  model
assessment  of  insulin  resistance;  HOMA-β:  —  homeostasis  model  assessment  of  β-cell
function; aadjusted for age, sex, and BMI
Figure 1. Association between body mass index and insulin resistance (A),  β-cell
dysfunction (B), and impaired fasting glucose (IFG) (C)
Figure  2. Prevalence  of  impaired  fasting  glucose  (IFG),  β-cell  dysfunction,  and
insulin resistance among nondiabetic patients by age (A) and sex (B). ***represented
p < 0.001
Figure 3. Association between body mass index and insulin resistance (A, D), β-cell
dysfunction (B, E), and impaired fasting glucose (IFG) (C, F) in nondiabetic 18–45-
(A–C) and > 45-year-old (D–E) individuals
Figure 4. Association between body mass index and insulin resistance (A, D), β-cell
dysfunction (B, E), and impaired fasting glucose (IFG) (C, F) in nondiabetic male
(A–C) and female (D–E) individuals
